Michael Allan, MD
Clinical Cardiac Electrophysiology · Fort Oglethorpe, GANPI 1124035571
Payments from drug & device makers
Across 217 payments — averaging $64.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$7K
- Boehringer Ingelheim$4K
- Abbott$1K
- Biosense Webster, Inc.$241
- Pfizer$200
- Lexicon Pharmaceuticals, Inc.$189
- plus $1K from 20 others
Across 6 payments — averaging $1027.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$6K
What the payments were for
- Speaking & faculty fees$6,82049%
- Travel & lodging$2,95721%
- Food & beverage$4,27630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 58 | $6,511 |
| Boehringer Ingelheim | 38 | $4,334 |
| Abbott | 19 | $1,366 |
| Biosense Webster, Inc. | 21 | $241 |
| Pfizer | 13 | $200 |
| Lexicon Pharmaceuticals, Inc. | 10 | $189 |
| Novartis | 9 | $187 |
| Cardiva Medical, Inc. | 7 | $182 |
| Baxter Healthcare | 6 | $141 |
| E.r. Squibb & Sons, L.L.C. | 6 | $100 |
| Kestra Medical Technology Services, Inc. | 5 | $97 |
| Heartflow, Inc. | 1 | $88 |
| Alnylam Pharmaceuticals Inc. | 3 | $60 |
| Medtronic(2 entities) | 3 | $48 |
| Novo Nordisk | 3 | $46 |
| Johnson & Johnson | 2 | $35 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Amgen | 2 | $32 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $25 |
| Amarin Pharma, Inc. | 1 | $25 |
| Merck | 1 | $21 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Cook Medical LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRADAXA$3,820
- Watchman$3,226
- AVEIR$829
- WATCHMAN Access System$119
How this compares
$14,053 in reported general payments places this provider in the 35th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
See all clinical cardiac electrophysiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 294 | $253,411 |
| XareltoRivaroxaban | 57 | $47,609 |
| EntrestoSacubitril/Valsartan | 40 | $30,867 |
| FarxigaDapagliflozin Propanediol | 48 | $30,361 |
| JardianceEmpagliflozin | 29 | $17,998 |
| MultaqDronedarone Hcl | 14 | $10,524 |
| Propafenone Hcl ErPropafenone Hcl | 34 | $7,115 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 32 | $5,402 |
| Flecainide Acetate | 87 | $4,118 |
| Propafenone Hcl | 91 | $3,611 |
| Enoxaparin Sodium | 17 | $3,341 |
| Digoxin | 170 | $2,877 |
| Mexiletine Hcl | 29 | $2,819 |
| Dofetilide | 21 | $2,245 |
| Metoprolol Succinate | 125 | $1,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $200 | $253,411294 claims |
| Johnson & JohnsonXarelto | $35 | $47,60957 claims |
| NovartisEntresto | $187 | $30,86740 claims |
| Boehringer IngelheimJardiance | $4,334 | $17,99829 claims |
| Sanofi-aventis U.S. LLCMultaq | $15 | $10,52414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
Other clinical cardiac electrophysiology in Fort Oglethorpe
- David DelurgioAtlanta$4.2M
- Alok GambhirGainesville$1.7M
- Kent NilssonAthens$1.4M
- David NewtonSavannah$1.4M
- Sandeep GoyalAtlanta$1.3M
- Mikhael El-ChamiAtlanta$1.1M
- Felix SogadeMacon$875K
- Sricharan KantipudiAtlanta$663K
- Anshul PatelAtlanta$615K
- Michael LloydAtlanta$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.